FDAnews
www.fdanews.com/articles/71837-abbott-presents-promising-zemplar-capsules-phase-iii-data

Abbott Presents Promising Zemplar Capsules Phase III Data

May 3, 2005

Abbott has presented the results of its pivotal Phase III clinical studies for Zemplar capsules in patients with Stage III and IV chronic kidney disease (CKD) who do not yet require dialysis. Study results indicate that Zemplar capsules provided significant and sustained reduction in parathyroid hormone (PTH) levels in predialysis Stage III and IV chronic kidney disease patients with secondary hyperparathyroidism (SHPT). The study compared Zemplar Capsules to placebo. Currently, many dialysis patients (Stage V) with SHPT are treated with the injectable form of Zemplar.

The results were presented at the National Kidney Foundation 2005 Spring Clinical Meetings. SHPT is a major complication associated with CKD. If left untreated, it can detrimentally impact bones and other vital organs, including the heart, muscles and nerves. Reduction in PTH level is a key indicator for SHPT treatment efficacy.